Aurobindo Pharma share news, announcements and annual reports
NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap
Aurobindo Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Jul 2000 on NSE
Last close ₹1,681.40up ₹21.50 (1.30%)BSE ₹1,677.80
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,659.90.
30 Oct: open ₹1,652.00, high ₹1,687.00, low ₹1,647.20
52-week range of traded prices to 30 Oct 2026
₹1,091.20Low, 30 Oct 2025₹1,740.00High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹96,744 Cr138th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.06
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.55
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 9,52,65057.5% delivered
Aurobindo Pharma share news and announcements
1,689 announcements, routine notices left out, newest first. Page 31 of 34.
Nov 2009
12 Nov · Dividend
Board of Directors of the Company at its meeting held on November 12, 2009 has inter-alia considered and approved the following: The final dividend at 30% (Rs.1.50 per share of Rs.5/- each) on the equity share capital of the Company for the year 2008-09 has been recommended, subject to the approval of members at the ensuing Annual General Meeting to be held on December 23, 2009.12 Nov · Business
Press release dated November 12, 2009, titled "Aurobindo Pharma receives final approval for Perindopril Erbumine Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Nov · Board meeting
To consider among other business, the Audited Annual Accounts of the Company for the year ended March 31, 2009 and also to recommend dividend, if any for the year ended March 31, 2009.9 Nov · Business
Press release dated November 09, 2009, titled "Aurobindo Pharma receives final approval for Cefotaxime for Injection USP". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Nov · Business
Press release dated November 06, 2009, titled "Aurobindo Pharma receives final approval for Lamotrigine Tablets from USFDA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Nov · Allotment of Equity Shares
In terms of the issue, the Bonds are convertible at any time on or after 20th September 2005 up to 1st August 2010 by the holders of the Bonds into Equity Shares of Rs.5/- each of the Company at a conversion price of Rs.522.036 per share with a fixed rate of exchange on conversion at Rs.43.3925 per US $ 1. Accordingly, pursuant to the application received for conversion from one of the Bondholders, the Committee of the Board of Directors of the Company at its meeting held on 04.11.2009 has considered the request and allotted 83,121 Equity Shares of Rs.5/- each for cash at a premium of Rs.517.036 by conversion of Bonds worth USD 1,000,000 in terms of the offer document to the FCCB holders. Consequent to the aforesaid allotment the paid up capital of the Company has gone up from 53,765,268 Equity Shares of Rs.5/- each to 53,848,389 Equity Shares of Rs.5/- each
Oct 2009
30 Oct · Management
Dr. D. Rajagopala Reddy has been appointed as an Additional Director of the Company at the Boar Meeting held on October 30, 2009. He will function as a Non Executive and Independent Director of the Company. Dr. S. Bimal Singh a Non Executive and Independent Director of the Company has resigned from the Board of the Company w.e.f. October 30, 2009.30 Oct · Results
Standalone Results for the half year ended on 30-SEP-2009 as follows: Net Sales of Rs. 158928 lacs for half year ending on 30-SEP-2009 against Rs. 127191 lacs for the half year ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 25440 lacs for the half year ending on 30-SEP-2009 against Rs. 137 lacs for the half year ending on 30-SEP-2008.30 Oct · Results
Consolidated Results for the half year ended on 30-SEP-2009 as follows: Net Sales of Rs. 173540 lacs for half year ending on 30-SEP-2009 against Rs. 138065 lacs for the half year ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 26977 lacs for the half year ending on 30-SEP-2009 against Rs. (2200) lacs for the half year ending on 30-SEP-2008.30 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2009 as follows: Net Sales of Rs. 88264 lacs for quarter ending on 30-SEP-2009 against Rs. 70099 lacs for the quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 10319 lacs for the quarter ending on 30-SEP-2009 against Rs. (3842) lacs for the quarter ending on 30-SEP-2008.30 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2009 as follows: Net Sales of Rs. 82631 lacs for quarter ending on 30-SEP-2009 against Rs. 62468 lacs for the quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 12829 lacs for the quarter ending on 30-SEP-2009 against Rs. (3850) lacs for the quarter ending on 30-SEP-2008.30 Oct · Business
Press release dated October 30, 2009, titled "Aurobindo Pharma Q2 2009-10 Unaudited Results". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Oct · Business
Press release dated October 29, 2009, titled "Aurobindo Pharma receives two registrations from MCC-South Africa". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Oct · Board meeting
To consider inter alia, the Un-audited Financial Results of the Company for the quarter and half year ended September 30, 2009.16 Oct · Meeting
Registrar of Companies, A.P. has granted extension of time to hold the Annual General Meeting of the Company for the accounting year ended on March 31, 2009 by two months i.e. till November 30, 2009.
Sep 2009
29 Sep · Business
Press release dated September 29, 2009, titled "Aurobindo Pharma receives prestigious Export Performance Award from Pharmexcil". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Sep · Business
Press release dated September 18, 2009, titled "Aurobindo Pharma receives three ANDA approvals from USFDA for Atomoxetine Hydrochloride Capsules, Ribavirin Tablets and Ribavirin Capsules". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Sep · Business
Press release dated September 07, 2009, titled "Aurobindo Pharma receives final approval for Risperidone Oral Solution". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 Sep · Business
Press release dated September 07, 2009, titled "Aurobindo Pharma receives Swissmedic approvals for Amlodipine Besylate Tablets and Metformin Hydrochloride Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Sep · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the quarter ended June 30,2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2009
27 Aug · Business
Press release dated August 27, 2009, titled "Aurobindo Pharma receives final approval for Clindamycin Hydrochloride Capsules". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.27 Aug · Business
Press release dated August 27, 2009, titled "Aurobindo Pharma receives Swissmedic approval for Cefepime for Injection". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Aug · Business
Vide its letter dated August 14, 2009, that: "The Board of Directors of Aurobindo Pharmaceuticals Limited ("APL") today approved the proposal to acquire 100% stake of Trident Life Sciences Limited ("TLSL") subject to suitable agreements being executed between the parties for the same and conditions customary to closing of the transaction". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Aug · Business
Press release dated August 11, 2009, titled "Aurobindo Pharma receives final approval for Sumatriptan Succinate Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 Aug · Business
Press release dated August 07, 2009, titled "Aurobindo Pharma receives its 100th ANDA approval from USFDA for Carisoprodol Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2009
31 Jul · Business
Press release dated July 31, 2009, titled "Aurobindo Pharma Q1 2009-10 Unaudited Results". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.31 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 75223 lacs for quarter ending on 30-JUN-2009 against Rs. 64723 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 12611 lacs for the quarter ending on 30-JUN-2009 against Rs. 3987 lacs for the quarter ending on 30-JUN-2008.31 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 80965 lacs for quarter ending on 30-JUN-2009 against Rs. 67966 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 16657 lacs for the quarter ending on 30-JUN-2009 against Rs. 1642 lacs for the quarter ending on 30-JUN-2008.29 Jul · Business
Press release dated July 29, 2009, titled "Aurobindo Pharma receives tentative approval for Donepezil Hydrochloride Tablets from USFDA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Jul · Business
Press release dated July 24, 2009 titled "Aurobindo Pharma's New Drug Applications Zidovudine Tablets 60mg and Lamivudine & Zidovudine Tablets 30mg/60mg receives USFDA Approvals". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Jul · Board meeting
Meeting on 31 Jul 2009: “Unaudited Financial Results for the Qtr ended June 30, 2009”10 Jul · Business
Press release dated July 10, 2009 titled "Aurobindo Pharma receives final approval for Fosinopril Sodium and Hydrochlorothiazide Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2009
18 Jun · Business
With reference to the earlier announcements dated 31st March, 2009 and 22nd May, 2009 regarding the Scheme of Arrangement between Aurobindo Pharma Limited and its Shareholders, it is now informed that as directed by the Hon'ble High Court of Judicature of Andhra Pradesh at Hyderabad by its Order dated 16th June, 2009, the Company, on 18th June 2009, has published the notice in News Papers about the date of hearing of the petition for the sanction of the Scheme of Arrangement between Aurobindo Pharma Limited and its Shareholders15 Jun · Business
Press release dated June 15, 2009 titled "Aurobindo Pharma receives approval for Amlodipine Besylate Tablets from TGA, Australia". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Jun · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the quarter ended March 31, 2009. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2009
29 May · Business
Press release dated May 29, 2009 titled "Aurobindo Pharma's US Joint Venture receives original generic approval for Ceftiofur Sodium Sterile Powder". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 May · Outcome of Court Convened Meeting
The Shareholders of the Company at their meeting held on Thursday, the 21st day of May 2009 at Hyderabad as per the directions of the Hon'ble High Court of Andhra Pradesh at Hyderabad, have approved the Scheme of Arrangement between the Company and its Shareholders by requisite majority. The Shareholders have also approved the resolution for the reduction of capital in the form of utilization of Capital Redemption Reserve Account as the proposed Scheme involves Utilization of the Capital Redemption Reserve Account and creation of Reconstruction Reserve Account21 May · Business
Press release dated May 21, 2009 titled "Aurobindo Pharma expands Licensing and Supply Agreement with Pfizer". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2009
30 Apr · Business
Press release dated April 30, 2009 titled "FY 2008-09 and Q4 2008-09 Unaudited Results". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Apr · Results
Consolidated Results for the quarter ended on 31-MAR-2009 as follows: Net Sales of Rs. 85005 lacs for quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 8004 lacs for the quarter ending on 31-MAR-2009.30 Apr · Results
Standalone Results for the quarter ended on 31-MAR-2009 as follows: Net Sales of Rs. 76998 lacs for quarter ending on 31-MAR-2009 against Rs. 63240 lacs for the quarter ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 9038 lacs for the quarter ending on 31-MAR-2009 against Rs. 7608 lacs for the quarter ending on 31-MAR-2008.29 Apr · Notice of Meeting
By an order made on April 18, 2009 in the Company Application, the Hon'ble High Court of Judicature of Andhra Pradesh at Hyderabad has directed that a Meeting of the Equity Shareholders of the Applicant Company i.e., Aurobindo Pharma Limited, be convened and held on May 21, 2009 for the purpose of considering and if thought fit approving, with or without modification(s), the arrangements embodied in the Scheme of Arrangement proposed to be made between Aurobindo Pharma Limited and its Shareholders. A copy of the Notice of Meeting shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Apr · Board meeting
To consider inter alia, the Un-audited Financial Results of the company for the quarter and year ended March 31, 2009.8 Apr · Business
Press release dated April 08, 2009 titled "Aurobindo Pharma receives first product approval from Swissmedic for Finasteride Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2009
31 Mar · Business
Press release dated March 31, 2009 titled "Aurobindo Pharma receives tentative approval for Emtricitabine / Tenofovir Disproxil Fumarate Tablets ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.31 Mar · Business
The Board of Directors of the Company approved the Scheme of Arrangement ("the Scheme") in their meeting held on March 31, 2009, which inter alia provides for the following: 1) Utilization of the Capital Redemption Reserve Account of Rs. 90.0 million outstanding as on March 31, 2008. 2) The gains arising on the buyback of FCCBs, being capital in nature, together with the amount of Rs. 90.3 million standing to the credit of Capital Reserve Account as on March 31, 2008 shall be credited to "Reconstruction Reserve Account". 3) The Capital Redemption Reserve Account and the Reconstruction Reserve Account shall be utilized at the discretion of the Board for adjusting the expenses of the nature such as diminution in value of investments, impairment of goodwill / assets etc., as would be described in the Scheme. 4) The scheme does not entail issue of any shares or other consideration to any of its shareholders. The Scheme is subject to requisite consent, approval of the requisite majority of the shareholders of the Company, the Hon'ble High Court of Judicature at Hyderabad, Stock Exchanges, the permission or approval of any other statutory or regulatory authorities, which by law may be necessary for the implementation of the Scheme.30 Mar · Business
Press release dated March 30, 2009 titled "Aurobindo Pharma receives final approval for Topiramate Tablets ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.27 Mar · Board meeting
To consider a Scheme of Arrangement.20 Mar · Business
Press release dated March 20, 2009 titled "Aurobindo Pharma receives second product approval from TGA, Australia for Sertraline Tablets ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Mar · Business
Press release dated March 20, 2009 titled "Aurobindo Pharma receives final approval for Fluoxetine Oral Solution". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.